Atomwise vs Biofourmis

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Atomwise employs 75 people, while Biofourmis has 100-500 employees.

Biofourmis has raised more in total funding at $445M, compared to Atomwise's $219M — a gap of $226M. Combined, the two companies have completed 5 known funding rounds.

Biofourmis holds the higher Awaira Score at 73/100, compared to Atomwise's 53/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 20-point gap that reflects meaningful differences in scale or traction.

Atomwise was founded by Abraham Heifets in 2012. Biofourmis was founded by Kuldeep Singh in 2015. Visit each company's profile on Awaira for a full founder biography.

Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform leverages machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development. Biofourmis: Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients.\n\nThe company raised approximately $445 million including a Series D from investors including SoftBank Vision Fund 2, Openspace Ventures, and Mass General Brigham Ventures. Biofourmis has built partnerships with health systems including Brigham and Women Hospital, Guy Hospital, and several major Asian health systems for remote monitoring program deployment, and has entered into pharmaceutical partnerships for using its digital monitoring platform as a clinical trial measurement tool to capture digital endpoints.\n\nBiofourmis competes in the remote patient monitoring and digital therapeutics market against BioIntelliSense, Current Health, and Validic, as well as the monitoring capabilities of established medical device companies including Philips and Masimo that are adding AI analytics to their remote monitoring platforms. The hospital-at-home model, which uses continuous remote monitoring AI to substitute inpatient hospital stays for selected patient populations, represents a significant healthcare cost reduction opportunity that health systems in the US, UK, and Asia are actively piloting.

Atomwise was founded first in 2012, giving it 3 years of additional market experience. Biofourmis was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Atomwise has approximately 75 employees, while Biofourmis has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Atomwise and Biofourmis are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.